Corient Private Wealth LLC Sells 5,152 Shares of Sanofi (NASDAQ:SNY)

Corient Private Wealth LLC reduced its stake in Sanofi (NASDAQ:SNY) by 5.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 98,296 shares of the company’s stock after selling 5,152 shares during the period. Corient Private Wealth LLC’s holdings in Sanofi were worth $4,741,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Synergy Asset Management LLC bought a new position in shares of Sanofi in the 4th quarter worth $25,000. McClarren Financial Advisors Inc. boosted its position in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Sunbelt Securities Inc. boosted its position in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the last quarter. Sierra Ocean LLC bought a new position in shares of Sanofi in the 4th quarter worth $44,000. Finally, Versant Capital Management Inc bought a new position in shares of Sanofi in the 4th quarter worth $54,000. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on SNY shares. The Goldman Sachs Group began coverage on Sanofi in a research report on Friday. They issued a “neutral” rating and a $65.00 price target on the stock. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sanofi has an average rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Price Performance

NASDAQ SNY opened at $56.90 on Friday. The business has a 50 day simple moving average of $54.55 and a 200 day simple moving average of $52.93. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a market cap of $144.40 billion, a price-to-earnings ratio of 22.85, a PEG ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.